Rep. Diana DeGette (D-Colo.) is considering a drug price bill that specifically addresses high insulin prices.
She told Bloomberg Law in an interview June 19 she was waiting to see how lawmakers would fair in drafting a drug price bill that was “more far ranging,” but “so far they haven’t really come up with one. So we may move ahead with just an insulin-based bill,” she said, referring to herself and Rep. Tom Reed (R-N.Y.).
Insulin prices have served as a case study for high drug prices for lawmakers on Capitol Hill. The most expensive drugs typically treat rare diseases ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.